Acute Lymphoblastic Leukemia as Secondary Malignancy in a Case of Ewing's Sarcoma on Treatment.
| Autor: | Satyarth S; Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India., Parikh S; Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India., Anand A; Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India., Sawhney J; Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India., Panchal H; Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India., Patel A; Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India., Shah S; Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology [Indian J Med Paediatr Oncol] 2017 Jul-Sep; Vol. 38 (3), pp. 354-356. |
| DOI: | 10.4103/ijmpo.ijmpo_110_16 |
| Abstrakt: | The survival of Ewing's sarcoma (ES) has improved due to advances in both local and systemic therapy. This has given rise to an increased detection of second malignant neoplasms which can be in the form of solid tumors and hematological malignancies. The most common hematological malignancies are acute myeloid leukemia/myelodysplastic syndrome. Acute lymphoblastic leukemia (ALL) is relatively uncommon in occurrence in this setting. Furthermore, the average refractory period for hematological malignancies varies from 3 to 5 years. We report a case of a young female who developed ALL while on adjuvant therapy for ES. Competing Interests: There are no conflicts of interest. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|